insulins

The agreement for up to ten biosimilar assets represents one of largest ever biosimilar collaborations for the company

The agreement will expand the pipeline and builds on an existing partnership

Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

An estimated 32 million people aged 50 years and over in Europe were living with osteoporosis in 2019

The drug is approved for inflammatory conditions such as Crohn's disease and plaque psoriasis

The drug has been approved to treat plaque psoriasis, psoriatic arthritis and Crohn’s disease

The facility is dedicated to developing and producing monoclonal antibodies, enzymes and other proteins

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

The split allows Sandoz to strengthen its position in generics and biosimilars

Hyrimoz HCF is approved to treat indications including rheumatoid arthritis and Crohn’s disease

The Novartis unit will aim to expand its current pipeline of biosimilars to about 24 candidates

The initiative wants to increase the global use of biosimilars by at least 30% by 2030